Clinical trials
PSMA PET clinical trials
Below are recruiting psma pet clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT03594760RecruitingPhase 3
PSMA PET scan study using advanced computer imaging in prostate cancer
This Phase 3 study looks at how a PSMA PET scan can predict how prostate cancer will progress and how well treatment is working. If your doctor at CHUM orders this scan, you may be able to join to help refine better predictions for future patients.
Montreal, QuebecAges 18 years+ - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT06859203Recruiting
PET scan study for men with rising PSA after prostate cancer treatment
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT06363435Recruiting
AI study of tumor burden on PSMA PET-CT scans
This trial tests an AI tool that measures tumor burden on PSMA PET-CT scans. If you are having this scan for prostate cancer, it could help doctors get more detailed information from your images.
LundAges 20–120 - NCT07056790RecruitingPhase 1/Phase 2
PET scan using 68Ga-PSMA-CYC for prostate cancer
This trial is testing a new type of PET scan that uses a special tracer called 68Ga-PSMA-CYC to take detailed pictures of prostate cancer. It may help doctors better see where the cancer is and how far it has spread.
Fuzhou, FujianAges 18–80 - NCT07209878RecruitingPhase 2/Phase 3
PET scan vs. MRI for prostate cancer diagnosis
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
Fuzhou, FujianAges 18–80 - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT07691697Recruiting
Targeted radiation for limited prostate cancer spread
This trial tests whether giving focused radiation to a small number of growing prostate cancer spots can help control the disease while you continue your current systemic treatment. It may delay the need to switch treatments and is for people whose cancer has spread to only a few places.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07150715RecruitingPhase 2
Radioactive drug plus precise radiation for recurrent prostate cancer
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
Los Angeles, CaliforniaAges 18 years+ - NCT06852820RecruitingPhase 2
PSMA-targeted radioactive therapy for advanced liver cancer
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
Cleveland, OhioAges 18 years+ - NCT07788625Recruiting
Focal therapy for prostate cancer not visible on MRI
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
Hong Kong, 香港島Ages 50 years+ - NCT06904313RecruitingPhase 2
Ultra-low dose PET scan for PSMA
This study tests a very low-dose PET scan to see if it can find prostate cancer cells that have PSMA on their surface. It might help you avoid higher radiation doses while still getting important images.
Englewood, New JerseyAges 18–120 - NCT06003556RecruitingPhase 2
PSMA-guided ablation for prostate cancer
This trial tests a targeted treatment for prostate cancer using PSMA imaging to guide ablation (removal) of the tumor. It may help men with early-stage, localized cancer that hasn't spread.
Calgary, AlbertaAges 50 years+ - NCT07569926RecruitingPhase 4
Fluciclovine PET scan for prostate cancer recurrence detection
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
San Diego, CaliforniaAges 18 years+ - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT06387381RecruitingEarly Phase 1
PET scan for PSMA/FAP-positive cancer
This trial tests a special PET scan using a tracer that attaches to certain markers (PSMA and FAP) found on some cancers. It aims to help doctors see where the cancer is, possibly leading to better treatment decisions.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05582876Recruiting
PET/MR scan to plan personalized prostate cancer treatment
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
BialystokAges 18–99 - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT06353321Recruiting
PSMA-PET imaging for guiding radiation therapy in prostate cancer
This study tests a new way to use a PSMA-PET scan (a special imaging test that finds prostate cancer cells) to guide a type of radiation treatment called BgRT. It is for men with prostate cancer who are already getting a PSMA-PET scan as part of their regular care.
Dallas, TexasAges Any age
Hear when a new PSMA PET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma pet?
- Yes. Clin2 currently lists 76 recruiting psma pet studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma pet trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma pet trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.